OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
09676056

JW Holdings Corp

PharmaceuticalsVerified

JW Holdings Corp maintains a capital structure with a debt-to-equity ratio of 1.35, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium, with a current ratio of 0.88, suggesting that its current liabilities exceed its current assets. This is further supported by the fact that its net cash position is negative after subtracting total debt, signaling potential short-term liquidity constraints. In terms of profitability, the company's return on equity (ROE) is 21.92%, which is a strong indicator of its ability to generate returns for shareholders. However, its return on assets (ROA) is 4.75%, which is relatively modest and may indicate that the company is not efficiently utilizing its assets to generate profits. These metrics should be compared against the industry median to determine whether the company is outperforming or underperforming its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher concentration risk, particularly if demand for its products fluctuates in its primary market. Looking at the company's growth trajectory, the available data does not provide specific forward-looking revenue projections or historical growth rates. However, the company's operating cash flow of 163.67 billion KRW and free cash flow of 85.88 billion KRW suggest that it has the capacity to fund operations and potentially invest in growth initiatives. The absence of detailed outlook data means that the company's future growth potential remains somewhat uncertain. The risk assessment for JW Holdings Corp highlights a medium liquidity risk, primarily due to its current ratio being below 1 and a negative net cash position after accounting for total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's reliance on debt financing could increase its financial risk if interest rates rise or if it faces difficulties in refinancing its debt. Recent events and filings have not been disclosed in the available data, so there is no information on any recent strategic moves, product launches, or regulatory changes that may impact the company's operations. The absence of such information limits the ability to assess the company's recent performance and strategic direction.

30-day price · 096760(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyJW Holdings Corp
Ticker096760.KS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. JW Holdings Corp is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Classification. JW Holdings Corp is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a classification confidence of 0.92.

JW Holdings Corp maintains a capital structure with a debt-to-equity ratio of 1.35, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium, with a current ratio of 0.88, suggesting that its current liabilities exceed its current assets. This is further supported by the fact that its net cash position is negative after subtracting total debt, signaling potential short-term liquidity constraints. In terms of profitability, the company's return on equity (ROE) is 21.92%, which is a strong indicator of its ability to generate returns for shareholders. However, its return on assets (ROA) is 4.75%, which is relatively modest and may indicate that the company is not efficiently utilizing its assets to generate profits. These metrics should be compared against the industry median to determine whether the company is outperforming or underperforming its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher concentration risk, particularly if demand for its products fluctuates in its primary market. Looking at the company's growth trajectory, the available data does not provide specific forward-looking revenue projections or historical growth rates. However, the company's operating cash flow of 163.67 billion KRW and free cash flow of 85.88 billion KRW suggest that it has the capacity to fund operations and potentially invest in growth initiatives. The absence of detailed outlook data means that the company's future growth potential remains somewhat uncertain. The risk assessment for JW Holdings Corp highlights a medium liquidity risk, primarily due to its current ratio being below 1 and a negative net cash position after accounting for total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's reliance on debt financing could increase its financial risk if interest rates rise or if it faces difficulties in refinancing its debt. Recent events and filings have not been disclosed in the available data, so there is no information on any recent strategic moves, product launches, or regulatory changes that may impact the company's operations. The absence of such information limits the ability to assess the company's recent performance and strategic direction.
Key takeaways
  • JW Holdings Corp has a strong return on equity (21.92%) but a modest return on assets (4.75%), indicating potential inefficiencies in asset utilization.
  • The company's liquidity position is medium, with a current ratio of 0.88 and a negative net cash position after subtracting total debt.
  • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed, which could increase concentration risk.
  • The company's debt-to-equity ratio of 1.35 suggests a moderate reliance on debt financing.
  • The company's operating and free cash flows are positive, indicating the ability to fund operations and potentially invest in growth.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$969.57B
Gross profit$491.47B
Operating income$174.02B
Net income$58.50B
R&D
SG&A
D&A
SBC
Operating cash flow$163.67B
CapEx-$54.70B
Free cash flow$85.88B
Total assets$1.23T
Total liabilities$964.22B
Total equity$266.96B
Cash & equivalents$71.83B
Long-term debt$359.62B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$266.96B
Net cash-$287.79B
Current ratio0.9
Debt/Equity1.4
ROA4.8%
ROE21.9%
Cash conversion2.8%
CapEx/Revenue-5.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric096760Activity
Op margin17.9%-2.9% medp25 -218.9% · p75 9.6%top quartile
Net margin6.0%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin50.7%47.8% medp25 27.6% · p75 68.9%above median
CapEx / revenue-5.6%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity135.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-20 12:23 UTCJob: 90129cd4